Biotechnology Industry
Filter News
Found 8,736 articles
-
BLINCYTO® (blinatumomab) Approved In Japan For The Treatment Of Relapsed Or Refractory B-cell Acute Lymphoblastic Leukemia
9/25/2018
First Approved Oncology Treatment From Amgen Astellas Joint Venture
-
Anaeropharma Science Signs Collaborative Research Agreement with Astellas on Creation of Novel Anti-Tumor Drugs Using Bifidobacterium
9/25/2018
Anaeropharma Science Inc. announced on September 25 that Anaeropharma and Astellas Pharma Inc. have concluded a collaborative research agreement concerning the creation of novel anti-tumor drugs that utilizes characteristic features of Bifidobacterium longum through Anaeropharma's proprietary platform technology, in situ Delivery and Production System ("i-DPS").
-
Atox Bio Announces Independent Safety Monitoring Committee Recommendation to Continue Phase 3 Study of Reltecimod in Necrotizing Soft Tissue Infections
9/25/2018
Atox Bio today announced the independent Data Monitoring Committee (DMC) completed its pre-planned safety review of the first 200 patients enrolled in the company's ACCUTE trial
-
PathoQuest Names Dr. Christiane Honisch to Board of Directors
9/25/2018
PathoQuest today announced the appointment of Christiane Honisch, Ph.D. as an independent member of the Company’s Board of Directors.
-
Physicians have long recommended fish oil to patients with high cholesterol and triglycerides, even though the scientific studies on it are mixed. Amarin developed a drug called Vascepa, which derives from a purified component of fish oil called eicosapentaenoic acid (EPA).
-
Some cancer cells have a remarkable and frightening sense of self-preservation to avoid immunotherapy treatments. That is the finding from a new study conducted by researchers at the Fred Hutchinson Cancer Research Center in Seattle.
-
The U.S. Food and Drug Administration (FDA) has a few target action dates scheduled for this week, including one for Sunday, September 23, which was approved in late August.
-
AstraZeneca announced positive results from its Phase III DECLARE-TIMI 58 cardiovascular outcomes clinical trial of Farxiga (dapagliflozin).
-
According to BioPharm Catalyst there were, or soon will be, 58 biopharma IPOs in 2018. And the trend doesn’t appear to be slowing. Here’s a look at five upcoming biotech IPOs.
-
BioSpace Movers and Shakers Sept. 24
9/24/2018
Here's a look at who's making moves in the biotech and pharma world this week. -
Epizyme, an innovative epigenetic therapy development company, announced this morning that the U.S. Food and Drug Administration has removed their former partial clinical hold reported in April of this year.
-
Sarepta Announces Clinical Hold Lifted for its Duchenne Muscular Dystrophy Micro-dystrophin Gene ...
9/24/2018
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicine to treat rare neuromuscular diseases, announced today that the Food and Drug Administration (FDA) has lifted the clinical hold for the Company's Duchenne... -
Alexion Announces Successful Phase 3 PREVENT Study of Soliris® (Eculizumab) in Patients with Neur...
9/24/2018
Soliris® Reduced the Risk of Adjudicated On-Trial Relapse by 94.2% Compared to Placebo (p < 0.0001). -
FARXIGA Achieved a Positive Result in the Phase III DECLARE-TIMI 58 Trial, a Large Cardiovascular Outcomes Trial in 17,000 Patients with Type 2 Diabetes
9/24/2018
FARXIGA met the primary composite endpoint of a statistically-significant reduction in hospitalization for heart failure or CV death in a broad patient population
-
ImmunoGen Announces Webcasts of Presentations at Upcoming October 2018 Conferences
9/24/2018
ImmunoGen, Inc. today announced that the following presentations by Company management at upcoming investor conferences will be webcast:
-
Shareholder Update September 24, 2018: Creative Medical Technology Holdings, Inc.
9/24/2018
Creative Medical Technology Holdings, Inc. announced today an update of its progress
-
Verastem Oncology Receives FDA Approval of COPIKTRA™ (duvelisib) Capsules
9/24/2018
Verastem Oncology (Nasdaq:VSTM) (Verastem Oncology or the Company), focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients, today announced that the U.S. Food and Drug Administration (FDA) has approved COPIKTRA™, an oral inhibitor of phosphoinositide 3-kinase (PI3K), and the first approved dual inhibitor of PI3K-delta and PI3K-gamma.
-
CAP Statement on US District Court Opinion on Lawsuit Against HHS
9/24/2018
College of American Pathologists President R. Bruce Williams, MD, FCAP issued the following statement after the U.S. District Court for the District of Columbia in American Clinical Laboratory Association (ACLA) v Azar:
-
Revance to Participate in the Cantor Fitzgerald 2018 Global Healthcare Conference
9/24/2018
Revance Therapeutics, Inc., (NASDAQ:RVNC), a biotechnology company developing neuromodulators for use in treating aesthetic and therapeutic conditions, today announced that the Company will participate in the Cantor Fitzgerald 2018 Global Healthcare Conference in New York, NY.
-
Avidity Science Acquires CT Chemicals Inc.
9/24/2018
Avidity Science is pleased to announce it has completed its acquisition of CT Chemicals Inc.